Perfusion Parameters and Outcome During a Standardized Deresuscitation Strategy with Net Ultrafiltration: a Retrospective Cohort Study.

Completed

• Conditions: Fluid Overload; Acute Kidney Injury; Continuous Renal Replacement Therapy

• Registration Number: NCT06899880
• Lead Sponsor: Hospices Civils de Lyon

Brief Summary

Hemodynamic tolerance of fluid removal during deresuscitation is a cornerstone of the impact on outcome of such a strategy. However, how to define and to predict hemodynamic tolerance to fluid removal remains controversial. The investigators routinely use a standardized deresuscitation protocol in patients with fluid overload and continuous renal replacement therapy combined with monitoring of clinical and biological perfusion parameters.

The aim of the study was to describe perfusion during deresuscitation, and to determine whether it is associated with major adverse kidney events at day 30.

Detailed Description

Not available

Study Timeline

• Study Start: 2024-01-01
• Primary Completion: 2024-03-01
• Study Completion: 2024-04-01
• Status Verified: 2025-03
• Study First Submitted: 2025-03-21
• Study First Submitted QC: 2025-03-21
• Last Update Submitted: 2025-03-21
• Study First Posted: 2025-03-28
• Last Update Posted: 2025-03-28

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 120

Inclusion Criteria

• Age ≥ 18 years old
• Acute kidney injury requiring continuous renal replacement therapy
• Standardized deresuscitation following a routine care protocol

Exclusion Criteria

• Chronic hemodialysis
• Advanced directives to withhold or withdraw life-sustaining treatment,
• Patient's opposition to the use of his/her personal health data

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
MAKE 30	A day 30 after the initiation of the deresuscitation strategy	Major adverse kidney event at day 30, defined as follows: * Death OR; * No weaning of renal replacement therapy OR; * Serum creatinine \> 2 times baseline serum creatinine

Trial Locations

Locations (1)

Louis Pradel Hospital; 🇫🇷 France, Bron, France